cRGD-targeted nano-platform with cabazitaxel prodrug and chlorin e6 achieves complete retinoblastoma ablation.

Retinoblastoma (RB), the most common pediatric intraocular cancer, faces significant treatment challenges. Current chemotherapies have severe systemic toxicities, often necessitating enucleation (eye removal) for advanced cases. There's a critical need for targeted, less invasive therapies that can precisely deliver agents to the tumor while sparing healthy tissue. This study explores a novel nanotechnology approach combining chemotherapy and photodynamic therapy (PDT) to achieve localized, amplified therapeutic effects. The goal is to overcome the limitations of systemic toxicity and improve patient outcomes.

Researchers engineered cRGD-functionalized nanoparticles co-assembling a dimeric cabazitaxel (CTX) prodrug (linked via a thioketal bridge) and the photosensitizer chlorin e6 (Ce6). These nanoparticles were designed for active targeting of integrin αvβ3, which is overexpressed in RB cells. In vitro, they assessed cellular uptake and potent cytotoxicity against Y79 RB cells upon near-infrared (NIR) irradiation. In vivo, an orthotopic xenograft RB mouse model was used to evaluate tumor accumulation, deep tissue penetration, and therapeutic efficacy after NIR irradiation, with systemic toxicity monitored.

The cRGD-decorated nanoparticles demonstrated superior cellular uptake and potent cytotoxicity against Y79 RB cells in vitro upon irradiation. Upon NIR light exposure, Ce6 generated a burst of cytotoxic ROS, which then cleaved the thioketal linkers, on-demand releasing active CTX monomers directly within the tumor microenvironment. This ROS-triggered drug release created a powerful positive feedback loop, amplifying the therapeutic effect.

In an orthotopic xenograft RB mouse model, the targeted nano-platform achieved complete tumor ablation after NIR irradiation. The study observed enhanced tumor accumulation and deep tissue penetration of the nanoparticles in vivo. Crucially, no observable systemic toxicity was reported, suggesting a favorable safety profile compared to conventional systemic chemotherapy. This self-amplifying mechanism ensures precise, localized drug activation and release, maximizing efficacy while minimizing off-target effects.